Author information from the last article
E-post: tor-morten.kvam@so-hf.no
Tor-Morten Kvam er spesialist i psykiatri, overlege ved Ketaminenheten, DPS nord, medlem av forskningsgruppen PsykForsk ved Sykehuset Østfold og ph.d.-kandidat ved Universitetet i Oslo.
Articles by Tor-Morten Kvam
Clinical and non-clinical use of MDMA
- Tor-Morten Kvam,
- Ivar W. Goksøyr,
- Lowan H. Stewart,
- Mark Berthold-Losleben,
- Ingrid Autran,
- Ole A. Andreassen
16.06.2026:
3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, has shown promising results in the treatment of post-traumatic stress disorder (PTSD). In clinical trials, the use of MDMA in combination with psychotherapy differs substantially from its illicit recreational use. MDMA is a central...
Ketamine in treatment-resistant depression
- Mark Berthold-Losleben,
- Ingrid Autran,
- Rikke Lise Steen Folstad,
- Benedikt Römer,
- Tor-Morten Kvam,
- Inger-Tove van de Vooren,
- Lowan H. Stewart,
- Ingmar Claussen,
- Ole A. Andreassen
24.04.2025:
Ketamine has a rapid antidepressant effect and appears to be a safe and effective treatment option for treatment-resistant depression. Depression is a common, serious illness that has a major negative impact on individuals, their families and society. Cardinal symptoms include low mood, loss of...
Ketamine for depression – evidence and proposals for practice
- Tor-Morten Kvam,
- Lowan H. Stewart,
- Andreas Wahl Blomkvist,
- Ole A. Andreassen
25.10.2021:
Current treatment for serious depression is unsatisfactory, and many patients fail to achieve the desired effect. Ketamine represents a new treatment option, and randomised trials show a rapid effect of intravenous ketamine. Although knowledge about adverse effects and the duration of the effect is...
Psychedelic drugs in the treatment of anxiety, depression and addiction
- Tor-Morten Kvam,
- Lowan H. Stewart,
- Ole A. Andreassen
12.11.2018:
In the 1950s and 60s, the classic psychedelic drugs lysergic acid diethylamide (LSD) and psilocybin were tested in numerous clinical trials. The results suggested efficacy against anxiety and depression in cases of life-threatening illness, unipolar depression and addiction (1–3). An open study of...